Showing 1236 results
-
Press Release /Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164…
-
Press Release /Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab Seven of ten patients discontinued eculizumab and remained on…
-
Press Release /At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with…
-
Press Release /Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported…
-
Ad-hoc Releases /Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple…
-
Ad-hoc Releases /Basel, August 17, 2020 — Novartis welcomes the decision by the US District Court for the District of Delaware to uphold the validity of the Gilenya® (fingolimod) dosage regimen patent, as our…
-
Press Release /EC approves Xolair® (omalizumab) as an add-on therapy for severe chronic rhinosinusitis with nasal polyps, the first anti-immunoglobulin E antibody approved in this indication1 Chronic…
-
Press Release /Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis1…
-
Press Release /Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously…
-
Press Release /EU approval is based on two Phase III studies showing Cosentyx® provides fast and strong skin clearance, along with significant improvement in quality of life and a favorable safety profile1 …